Dear AuntMinnie Member,
The U.S. PET and PET/CT market rang up revenue of nearly $500 million last year. That sum is expected to climb to $725.1 million in less than a decade, no doubt aided by the latest clinical research proving PET/CT's value in disease diagnosis and treatment.
To that end, two recent studies demonstrated the alacrity of PET/CT in lung cancer. The first found that PET/CT had higher sensitivity, specificity, and positive and negative predictive values than either modality alone for detecting lung metastases. The second compared the accuracy of PET, hardware fusion, and software fusion in patients with non-small cell lung cancer (NSCLC). Click here to read more about this research in an article by staff writer Eric Barnes.
While you're visiting our Molecular Imaging Digital Community, be sure to check out the latest updates to Nuclear Medicine on the Internet. This online reference by Dr. Scott C. Williams is an excellent way to brush up on the basics of PET in oncologic imaging, including lung cancer staging.
